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Abstract: Preclinical data on extracts of and preparations derived from beans of Phaseolus 
vulgaris are reviewed as potential remedies for use in controlling food consumption, body weight, 
lipid accumulation, and glycemia. A growing body of evidence suggests that acute and chronic 
administration of P . vulgaris derivatives reduces food intake (including highly palatable foods), 
body weight, lipid deposit, and glycemia in rats exposed to multiple experimental procedures. Two 
possible lectin-mediated mechanisms of action have been proposed: (a) inhibition of α-amylase, 
resulting in a reduced carbohydrate metabolism and absorption; (b) phytohemoagglutinin-
induced modulation of the activity of cholecystokinin and glucagon-like peptides, resulting in 
a reduced appetite. Preliminary clinical data, as well as reports focusing on the use of several 
traditional medicines, apparently extend these findings to humans. Should these initial clinical 
data be confirmed by future surveys, P . vulgaris derivatives might constitute novel remedies for 
the treatment of obesity and metabolic syndrome. Future studies are also expected to identify 
active structures leading to the development of new pharmaceutical agents.
Keywords: Phaseolus vulgaris extracts and derivatives, food intake, body weight, lipid 
accumulation, glycemia, obesity, diabetes, metabolic syndrome
This paper reviews the accumulating lines of experimental evidence suggesting that 
extracts of beans from Phaseolus vulgaris (Fabaceae) may be capable of reducing food 
intake (including highly palatable foods and fluids), body weight, lipid deposit, and 
glycemia in different, validated animal models of overeating, obesity, diabetes, and 
metabolic syndrome. A brief mention of the most relevant surveys testing P . vulgaris 
preparations on food intake and glycemia in humans is also given.
The genus P. vulgaris includes all species of legume seeds normally known as 
common beans. Archeological investigations showed that common beans originated 
on the American Continent, specifically in southern United States, Mexico, Central 
America, and the northern part of South America. In particular, the species P . vulgaris 
was introduced into Europe in the sixteenth century and since then it has become 
a very important crop in many regions of the world. Legume seeds are among the 
richest food sources of proteins, amino acids, complex carbohydrates, dietary fibers, 
and oligosaccharides for human and animal nutrition.1
P. vulgaris extracts and food intake in laboratory animals
Preclinical investigations have unanimously reported how the acute, repeated 
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reduced food intake, body weight, and lipid accumulation in 
lean and obese laboratory animals.2–13
Specifically, a study was performed to investigate the effect 
of a P . vulgaris extract mixed with a starch-enriched chow on 
food intake and body weight in young, lean Hooded Lister 
rats.6 Restricted amounts of food were made available to rats 
to ensure the entire supply of P . vulgaris extract was consumed 
by each rat. The results of this study indicated a significant 
reduction in body weight gain in rat groups consuming chow 
mixtures containing 20 and 40 mg/die P . vulgaris extract. The 
extract used in this study had a high content of α-amylase 
inhibitors, suggesting that the possible mechanism of action 
underlying the reducing effect produced by this P . vulgaris 
extract on body weight gain was constituted by inhibition of the 
pancreatic enzyme α-amylase, hampering starch metabolism 
and reducing feed efficiency (ie, food was less efficaciously 
converted into energy and, in turn, into body mass). Notably, 
the reduction in body weight gain secondary to exposure to 
the P . vulgaris extract was associated to a decrease in body 
content of lipids. Similar data were generated by a previous 
study, in which rats were fed with chow containing α-amylase 
inhibitors from P . vulgaris; rats displayed a decrease in body 
weight gain and lipid accumulation.4
Two studies evaluated the effect of prolonged (700 to 
800 consecutive days) exposure to a starch-enriched diet 
containing a P. vulgaris preparation.6,7 One of these two 
studies was designed to ensure that rats exposed to the 
90 g/kg kidney bean-based diet and pair-fed control rats 
(a) weighed approximately 100 g at the start of the experiment 
and (b) entirely consumed a fixed daily supply of food 
(resulting, in the treated rat group, in the consumption of the 
full daily dose of P . vulgaris extract).7 As shown in Figure 1, 
feed efficiency (defined as the body weight gain over the 
amount of food intake) was largely lower, especially over the 
first 3-month period, in P . vulgaris extract-treated rats than 
in control rats. Additionally, a significant reduction in body 
content of lipids was observed throughout the study in the 
rat group exposed to the P . vulgaris extract-containing diet 
when compared to the rat group exposed to the P . vulgaris 
extract-free diet.7 In the second study, control rats (exposed 
to a P . vulgaris extract-free diet) had a mean body weight 
gain of approximately 660 g; conversely, rats consuming the 
diet including the P . vulgaris extract displayed a mean body 
weight gain of approximately 470 g.6
An additional study investigated the effect of repeated 
(21 consecutive days) daily administration, by intragastric 
gavage, of a single dose (50 mg/kg) of an extract of P . vulgaris 
prepared to contain high amounts of α-amylase inhibitors 
on daily food intake and body weight in Wistar rats given 
access to a starch-enriched diet.2 Administration of the 
P . vulgaris extract resulted in a 15% reduction, in comparison 
to vehicle-treated control rats, in food intake over the 21-day 
treatment period; this effect was associated with a reduction 
in body weight gain (+52.0 g per rat and −1.3 g per rat 
in the vehicle- and P. vulgaris extract-treated rat groups, 
respectively, at the end of the treatment period).
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Figure 1 reducing effect of the prolonged (700 consecutive days) ingestion of a Phaseolus vulgaris preparation, mixed in a starch-enriched diet, on feed efficiency [defined as 
the body weight gain (g) over the amount (g) of food intake] in Hooded Lister rats. Adapted from Grant G, Dorward PM, Buchan wC, Armour JC, Pusztai A. Consumption 
of diets containing raw soya beans (Glycine max), kidney beans (Phaseolus vulgaris), cowpeas (Vigna unguiculata) or lupin seeds (Lupinus angustifolius) by rats for up to 700 days: 
effects on body composition and organ weights. Br J Nutr. 1995;73:17–29.7 Copyright © 1995 with permission of Cambridge University Press.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 147
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Notably, these results were subsequently replicated in 
a study using rats with streptozotocin-induced diabetes.13 
The repeated (22 consecutive days) daily administration of a 
single dose (100 mg/kg) of the P . vulgaris extract used in the 
previous study with Wistar rats (see also above) resulted in 
an approximately 25% reduction in daily food intake.12 This 
effect was paralleled by a reduction in body weight gain.
Beside the action of α-amylase inhibitors, another mecha-
nism for the reducing effect of P . vulgaris extracts on food 
intake and body weight has been proposed. As described in 
detail below, this mechanism involves phytohemoagglutinin, 
a lectin present at high levels in P. vulgaris. A series of 
experiments has been conducted to test this hypothesis. 
Specifically, an extract of P. vulgaris characterized by a 
high phytohemoagglutinin content was mixed to the diet; 
genetically obese Zucker rats were exposed to restricted 
daily amounts of food to ensure ingestion of the entire daily 
dose of phytohemoagglutinin by all rats.9 Repeated exposure 
to this diet resulted in reductions of 25% and 20%, in com-
parison to control rats (given an identical daily amount of 
phytohemoagglutinin-free chow), in body weight gain and 
body fat content, respectively. In an additional experiment11 
purified phytohemoagglutinin from P. vulgaris beans was 
acutely administered (by intragastric gavage), at a dose of 
100 mg/kg, to fasted Wistar rats given access to regular rat 
chow. Treatment with phytohemoagglutinin resulted in a 
marked reduction in food intake throughout the entire dark 
phase of the light/dark cycle (ie, the period of maximal activ-
ity in rats). The reducing effect of phytohemoagglutinin had 
a relatively slow onset, being manifest after approximately 
5 hours; at the end of the dark phase, food intake was reduced 
by approximately 40% in phytohemoagglutinin-treated rats 
in comparison to vehicle-treated rats.
This laboratory has recently conducted a study aimed at 
assessing the effect of a P . vulgaris extract prepared in order 
to produce a potential dual action: inhibition of α-amylase 
and a phytohemoagglutinin-induced anorectic effect. To this 
end BeanBlock® (prepared by Indena SpA, Milan, Italy), the 
extract tested, exerted an inhibitory activity on α-amylase 
equal to 1400 U/mg and an hemoagglutinating activity equal 
to 16 HAU/mg. The extract was added to a starch-enriched 
diet (Altromin RP 1000®; Rieper, Vandoies, Italy); pellets 
containing 0%, 0.5%, 1%, and 3% P . vulgaris extract were 
prepared. Singly housed, male adult Wistar rats (Charles 
River Laboratories, Calco, Italy) were divided into 4 groups 
of n = 6 to 7, matched for body weight, and fed with the 
above-mentioned food pellets with unlimited access for 
24 hours/day over 10 consecutive days (treatment phase). 
Rats from all groups were then given unlimited access to 
the plain diet (with 0% P . vulgaris extract) for an additional 
14 consecutive days (post-treatment phase). Food and water 
intake, as well as rat body weight, were recorded once a day.
Exposure to the four different diets resulted in a 
concentration-dependent suppression in daily food intake 
over the first 3 days of treatment (Figure 2, top panel). On 
days 1 and 2, daily food intake in the rat group exposed to 
the diet containing 3% P . vulgaris extract was approximately 
90% lower than that recorded in control rats (fed with the 
0% P . vulgaris extract). However, on continuing treatment, 
tolerance to the anorectic effect of the P . vulgaris extract 
developed, as indicated by the virtually complete lack of 
any difference in daily food intake among the four rat groups 
from day 8 of treatment (Figure 2, top panel). This tolerance 
developed even though rats exposed to the most concen-
trated diets ingested daily amounts of P. vulgaris extract 
2 to 3 times higher than those ingested during the first days 
of treatment. In the post-treatment phase, a relatively long 
period of overeating developed; this phenomenon was depen-
dent on concentration of the P . vulgaris extract included in 
the previous rat diet and peaked up to 50%, in comparison to 
control rats, on day +4 in the 3% P . vulgaris extract-treated 
rat group (Figure 2, top panel). Overeating tended to decrease 
progressively and vanished when rat body weight virtually 
achieved control values (see below).
Reduced daily water intake was observed only in the 
rat group consuming the 3% P . vulgaris extract; however, 
this effect vanished on continuing treatment (Figure 2, 
center panel). Erratic differences in daily water intake were 
observed among the four rat groups during the 14-day post-
treatment period (Figure 2, center panel).
In agreement with the reducing effect on food intake, 
rat body weight was greatly reduced in a concentration-
dependent fashion by the ingestion of P. vulgaris extract 
(Figure 2, bottom panel). Specifically, in the rat group 
exposed to the diet containing 3% P . vulgaris extract, the 
reduction in body weight peaked up to 8% on day 3, respect to 
values recorded immediately prior to start of the experiment. 
In the post-treatment phase, overeating (see above) led to a 
regaining of rat body weight (Figure 2, bottom panel); indeed, 
rate of rat body weight increase varied between control rats 
and animals previously exposed to the P . vulgaris extract.
P. vulgaris extracts and intake of 
palatable food in laboratory animals
Recent lines of evidence indicate that P . vulgaris extracts may 
also be effective in reducing intake of highly palatable foods. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 148
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Figure 2 reducing effect of the repeated (10 consecutive days) ingestion of a Phaseolus vulgaris extract, mixed – at the concentrations of 0%, 0.5%, 1% and 3% – to a starch-
enriched diet, on daily food (top panel) and water (center panel) intake, as well as changes in body weight (expressed as percent of baseline) (bottom panel) in wistar rats. 
each point is the mean ± SeM of n = 6 to 7 rats. Hatched vertical lines indicate the end of the 10-day treatment phase and the start of the 14-day post-treatment phase. 
ANOvA results – Food intake, treatment phase: Fdiet (3,21) = 10.42, P  0.0005; Ftime (9,189) = 22.58, P  0.0001; Finteraction (27,189) = 8.79, P  0.0001; Food intake, post-
treatment phase: Fdiet (3,21) = 12.93, P  0.0001; Ftime (13,273) = 43.78, P  0.0001; Finteraction (39,273) = 1.69, P  0.01;   water intake, treatment phase: Fdiet (3,21) = 3.47, P  0.05; 
Ftime (9,189) = 2.38, P  0.05; Finteraction (27,189) = 0.97, P  0.05; water intake, post-treatment phase: Fdiet (3,21) = 0.40, P  0.05; Ftime (13,273) = 14.76, P  0.0001; Finteraction 
(39,273) = 2.60, P  0.0001; Body weight changes, treatment phase: Fdiet (3,21) = 7,44, P  0.005; Ftime (9,189) = 79.94, P  0.0001; Finteraction (27,189) = 3.23, P  0.0001; Body 
weight changes, post-treatment phase: Fdiet (3,21) = 2.31, P  0.05; Ftime (13,273) = 458.37, P  0.0001; Finteraction (39,273) = 6.55, P  0.0001.
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As an example, a recent study by this laboratory found that 
the acute administration of a P . vulgaris extract (BeanBlock®) 
suppressed the intake of butter cookies in pre-satiated rats. 
Specifically, singly housed adult male Wistar rats (Charles 
River Laboratories) were habituated to feed [standard rat 
chow (Mucedola, Settimo Milanese, Italy)] for 3 hours per 
day (the first 3 hours of the dark phase); no food was available 
during the remaining 21 hours. Water was available 24 hours 
per day. This procedure led to fully satiated rats at the end of 
the 3-hour feeding period. On the test day, the 3-hour period 
of access to regular food was followed by 1-hour availability 
of the highly palatable butter cookies. Rats were divided 
into 4 groups of n = 7, matched for body weight and food 
intake during the last 3 days preceding the experiment. The 
P . vulgaris extract was administered intragastrically at doses 
of 0, 50, 200, and 500 mg/kg at the time of removal of the 
regular food (immediately prior to presentation of the butter 
cookies). Intake of butter cookies was recorded at the end of 
the 1-hour exposure period.
Even though rats were fully satiated, vehicle-treated rats 
consumed large amounts of butter cookies over the 1-hour 
exposure period. Acute administration of the P. vulgaris 
extract resulted in a dose-dependent suppression of this extra-
intake of food. Specifically, intake of butter cookies in rats 
treated with 50, 200, and 500 mg/kg P . vulgaris extract was 
approximately 75%, 85%, and 90% lower, respectively, than 
that recorded in vehicle-treated rats (Figure 3).
Another experiment (this laboratory, unpublished results) 
found that the same P . vulgaris extract previously tested in 
the experiment with the butter cookies (see above) dose-
dependently suppressed the polydipsic-like consumption 
of a highly palatable, chocolate-flavored beverage in rats. 
Notably, the P . vulgaris extract was shown to be more potent 
and effective in reducing intake of the chocolate-flavored 
beverage than regular food pellets. In that particular study, 
the chocolate-flavored beverage provided a modest caloric 
supply (1/15 than that provided by regular food pellets), 
resulting in a beverage mostly consumed by rats because of 
its palatability rather than its caloric properties. This suggests 
that P . vulgaris extracts may exert their suppressing effects 
on palatable food with mechanisms other than those related 
to the nutritive properties of food.
P. vulgaris extracts and glycemia 
in laboratory animals
P. vulgaris extracts have also been found to reduce 
glycemia12–14 and glucose absorption5 in laboratory animals. 
As an example, the study by Tormo et al in which rats were 
repeatedly treated with 50 mg/kg of P. vulgaris extract 
(with a high content of α-amylase inhibitors) and fed with a 
starch-enriched diet, demonstrated that the reducing effect 
of P . vulgaris extract on food intake and body weight was 
associated with a steady reduction in glycemia, measured 
once every other day and 1 hour after lights-off (this time 
schedule was likely chosen to measure the glycemia derived 
from the last daily meal, that usually occurs in the last period 
of the dark phase of the light/dark cycle under which rats 
were housed).12 An additional experiment found that acute 
administration of the same P . vulgaris extract reduced gly-
cemia in rats forcedly administered (by intragastric gavage) 
with a fixed amount (2 g/kg) of potato starch.12
Similar results were collected in rats made diabetic by 
treatment with streptozotocin.13 Specifically, newborn rats 
were treated with streptozotocin to induce pancreatic injury, 
resulting in reduction of insulin content and hyperglycemia; 
in adulthood, rats were treated daily and for 22 consecutive 
days with 100 mg/kg P. vulgaris extract; glycemia was 
assessed every other day, 1 hour after lights-off. Treatment 
with P . vulgaris extract resulted in (a) a marked and progres-
sively increasing reduction in glycemia in streptozotocin-
treated rats, reaching – at the end of the treatment – the values 
of vehicle-treated nonstreptozotocin-treated rats (Figure 4), 
and (b) a less marked – although significant – reduction in 
glycemia in non-streptozotocin-treated rats (Figure 4).
When P. vulgaris extracts with high contents of phyto-
hemoagglutinin and low contents of α-amylase inhibitors 
were tested, a lack of effect on glycemia was the most 
common outcome. As an example, repeated exposure to 
fixed amounts of phytohemoagglutinin-enriched diets 
resulted in slight, if any, reductions in glycemia in normal 
and obese rats.9–15
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Figure 3 reducing effect of the acute administration of a Phaseolus vulgaris extract on 
intake of butter cookies in pre-fed satiated wistar rats having a 1-hour access to butter 
cookies. each bar is the mean ± SeM of n = 7 rats.   ANOvA results: F (3; 27) = 245.55, 
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A recent experiment by this laboratory compared the 
effect of identical doses of a P . vulgaris extract (BeanBlock®), 
prepared to contain both α-amylase inhibitors and phytohe-
moagglutinin, and the standard anti-hyperglycemic drug, 
metformin, in rats. Specifically, singly housed adult male 
Wistar rats were fasted 24 hours before the start of the experi-
ment. On the test day, rats were divided into 4 groups of n = 7 
to 8, matched for body weight and glycemia, and treated 
intragastrically with vehicle, 500 mg/kg metformin (Sigma, 
Milan, Italy), and 500 mg/kg P . vulgaris extract. Thirty min-
utes later, rats were given 9 g/kg food [starch-enriched chow 
(Altromin RP 1000®; Rieper, Vandoies, Italy); an amount 
totally consumed – in less than 60 minutes – by fasted rats]. 
Glycemia was determined 0, 60, 120, and 360 minutes after 
food presentation. A small (0.05 mL) blood sample was 
collected from the tip of the tail of each rat and analyzed 
enzymatically [GL5 Analox® (Analox Ltd, London, UK)].
Metformin and P . vulgaris extract exerted a similar effect, 
inducing a reduction in glycemia of comparable magnitude 
at both 60- and 120-minute recording times (Figure 5, top 
panel). Accodingly, metformin and P . vulgaris extract reduced 
to a similar extent the area under the curve of the time-course 
of glycemia (Figure 5, bottom panel). These data indicate that 
P . vulgaris extracts may produce a reduction in post-prandial 
glycemia closely resembling that produced by metformin in 
rats exposed to a semi-naturalistic setting of a large meal 
after several hours fasting.
Possible mechanisms of action
Review of the existing literature suggests the involvement 
of two possible mechanisms of action in the reducing 
effect of P . vulgaris extracts on food intake, body weight, 
and glycemia. Both these mechanisms focus on the role of 
phytohemoagglutinin and α-amylase inhibitors. The latter 
constituents belong to the class of lectins, highly repre-
sented in different cereals and pulses, including P . vulgaris. 
These lectins – together with arcelins, another type of 
lectins abundant in P . vulgaris – are homologous proteins 
displaying high degrees (40% to 95%) of aminoacid sequence 
similarity.16–19
Pancreatic α-amylase is an enzyme that catalyzes hydro-
lysis of α-(1,4)-glycosidic bonds of starch polymers.20 Thus, 
inhibition of α-amylase results in the suppression of starch 
metabolism and, in turn, a decrease in glycemia.12–20 It has 
also been reported that α-amylase inhibitors delay gastric 
emptying, producing feelings of satiety,21–22 thus resulting 
in reduced food intake.12–13
Phytohemoagglutinin is known to bind to the stomach 
epithelial cells and to the brush border membrane of small 
intestine, cecum, and colon.5,11,23–25 This binding results in the 
stimulation of the release of cholecystokinin and glucagon-
like peptides,11,23–26 two hormones playing a relevant role in 
digestive processes and also in the central control of appetite. 
In close agreement with the latter hypothesis, recent data from 
this laboratory indicate that treatment with the cholecystoki-
nin receptor typeA (CCKA) antagonist, lorglumide, blocked 
the reducing effect of a P. vulgaris extract (BeanBlock®) 
on food intake in rats (this laboratory, unpublished results), 
suggesting that phytohemoagglutinin-stimulated release of 
cholecystokinin and CCKA receptors are major players in the 
appetite-reducing effect of P . vulgaris extracts.
Another CCKA receptor-mediated action of phytohe-
moagglutinin is the stimulation of pancreatic secretion of 
α-amylase in rats;27–29 this should result in an accelerated 
metabolism of ingested starch and, in turn, in a stimulation 
of food intake and increase in glycemia. However, this effect 
seems to be of limited relevance in the overall control of 
appetite and food intake, as it is likely overwelmed by the 
opposite, anorectic and hypoglycemic effects of phytohemo-
agglutinin itself and α-amylase inhibitors.
Human data and conclusions
As reported above and recently discussed,10,30 accumulating 
lines of experimental evidence consistently indicate that 
extracts of P. vulgaris are effective in reducing appetite, 
body weight, lipid accumulation, hedonic properties of food, 
starch absorption and metabolism, and glycemia in different 
species of laboratory animals.
These data are consonant with reports on a traditional 
use, mainly in Central American and European Countries, 
of P. vulgaris preparations as “antidiabetic” remedies. 
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Figure 4 reducing effect of the repeated (22 consecutive days) administration of a 
Phaseolus vulgaris extract on glycemia in control (ND) and streptozotocin-treated (STZ) 
rats.  Glycemia was monitored every other day.   Adapted from Tormo MA, Gil-exojo i, 
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Accordingly, considerable benefit – especially during the 
developmental stages of the disease – has been reported 
in individuals taking P . vulgaris or preparations containing 
P . vulgaris as a main constituent.30,31–35
An interesting clinical trial, conducted in healthy 
subjects, found that intraluminal administration of a 
P . vulgaris-derived α-amylase inhibitor suppressed (a) amy-
lase activity in duodenum, jejunum, and ileum, (b) early post-
prandial glycemia rise, and (c) late post-prandial glycemia 
fall (secondary to a marked decrease in post-prandial insu-
line release).36–37 Confirmation of the hypoglycemic effect 
of a P. vulgaris-derived α-amylase inhibitor is provided 
by a further study38 in which the α-amylase inhibitor was 
administered to healthy subjects, resulting in a significant 
reduction in post-prandial glycemia. Further, Brugge and 
Rosenfeld39 investigated the effect of a P. vulgaris-derived 
α-amylase inhibitor on hydrogen content in breath air 
after a starch-rich meal (spaghetti) in healthy subjects; 
breath hydrogen is inversely correlated with carbohydrate 
absorption. The P. vulgaris-derived α-amylase inhibitor 
produced a 2-fold increase in hydrogen excretion rate 
compared to control subjects, suggesting a decreased 
carbohydrate absorption and/or metabolism. Similar results 
were collected by Boivin et al.38 In a recent additional 
series of studies, tendencies toward a reduction in body 
weight and waist circumference were observed in healthy 
subjects taking a preparation of P. vulgaris.40–42 Finally, a 
more recent randomized, double-blind, placebo-controlled 
trial found that a 2-month treatment with a dietary supple-
ment made up of P. vulgaris and Cynara scolymus extracts 
increased the feeling of satiation (measured by the Haber’s 
scale for hunger/satiety scoring) in healthy overweight and 
obese subjects.43
Together, these data suggest that extracts of P . vulgaris 
may constitute potentially interesting, novel remedies for 
the treatment of overweight and metabolic syndrome. Future 
studies, designed to confirm and extend those currently 
available in literature, are needed. Confirmation of the above-
mentioned, promising data would also allow a re-evaluation 
of P. vulgaris preparations, the reputation of which has 
20000
+ +
16000
12000
8000
4000
0
P. vulgaris
500 mg/kg
Vehicle
A
r
e
a
 
u
n
d
e
r
 
t
h
e
 
c
u
r
v
e
(
m
g
*
m
 
i
n
/
d
L
)
Metformin 
500 mg/kg
160
140
120
100
80
60
G
l
y
c
e
m
i
a
 
(
m
g
/
d
l
)
0 60 120 180 240 300
Time (min)
360
Vehicle
Metformin 500 mg/kg
P. vulgaris 500 mg/kg
Figure 5 Similar reducing effect of a Phaseolus vulgaris extract and metformin on time-course of glycemia (top panel) and area under the curve of the time-course of glycemia 
(bottom panel) in wistar rats given a 1-hour (corresponding to the 0- to 60-minute time interval) access to a starch-enriched diet and water. each point or bar is the mean ± 
SeM of n = 7 to 8 rats. ANOvA results – Time-course: Ftreatment (2,20) = 9.13, P  0.005; Ftime (2,40) = 21.95, P  0.0001; Finteraction (4,40) = 10.95, P  0.0001; Area under the 
curve: F (2,20) = 7.23, P  0.005. *P  0.005 with respect to values of vehicle-treated rats at the same time interval (Newman-Keuls test); +P  0.05 with respect to values 
of vehicle-treated rats (Newman-Keuls test).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 152
Carai et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
frequently been hampered by the development of commercial 
preparations supported by large advertising campaign but 
devoid of any clinically demonstrated efficacy.
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